OncoMatch/Clinical Trials/NCT05548296
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Is NCT05548296 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including ACR-368 and Gemcitabine for endometrial adenocarcinoma.
Treatment: ACR-368 · Gemcitabine — This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Disease stage
Metastatic disease required
Grade: high-grade
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
Subject must have received prior platinum-based chemotherapy
Must have received: anti-PD-1 therapy
Subject must have received prior anti-PD-(L)1 therapy
Cannot have received: cell cycle CHK1 inhibitor (ACR-368)
Participant has taken a prior cell cycle CHK1 inhibitor, including ACR-368
Lab requirements
Blood counts
Absolute neutrophil count > 1500 cells/µL without growth factor support within 1 week prior to obtaining the hematology values at Screening. Hemoglobin ≥ 9.0 g/dL. Platelets ≥ 150,000 cells/µL without transfusion within 1 week prior to obtaining the hematology values at Screening.
Kidney function
GFR ≥ 50 mL/min/1.73m2 (may be estimated or measured by site standard methods)
Liver function
AST and ALT ≤ 3 × ULN; ≤ 5 × ULN if liver metastases are present. Total bilirubin ≤ 1.5 × ULN not associated with Gilbert's syndrome. If associated with Gilbert's syndrome ≤ 3 x ULN is acceptable. Serum albumin ≥ 3 g/dL.
Participant must have adequate organ function at Screening, defined as: Absolute neutrophil count > 1500 cells/µL without growth factor support within 1 week prior to obtaining the hematology values at Screening. Hemoglobin ≥ 9.0 g/dL. Platelets ≥ 150,000 cells/µL without transfusion within 1 week prior to obtaining the hematology values at Screening. Renal function is defined as GFR ≥ 50 mL/min/1.73m2. AST and ALT ≤ 3 × ULN; ≤ 5 × ULN if liver metastases are present. Total bilirubin ≤ 1.5 × ULN not associated with Gilbert's syndrome. If associated with Gilbert's syndrome ≤ 3 x ULN is acceptable. Serum albumin ≥ 3 g/dL.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of South Alabama Mitchell Cancer Institute · Mobile, Alabama
- Alaska Women's Cancer Center · Anchorage, Alaska
- HonorHealth · Phoenix, Arizona
- Arizona Oncology Associate, PC- HOPE · Tucson, Arizona
- University of Arkansas for Medical Sciences · Little Rock, Arkansas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify